## Institutional Interest in Surgical Science Sweden AB (OM:SUS) Shifts as Valuation Estimates Drop Sharply

Recent analyst activity around Surgical Science Sweden AB has painted a more cautious picture for the Swedish medical technology firm. The consensus one-year valuation estimate now sits at 73.44 kr per share, representing a significant 32.24% downward revision from the previous 108.38 kr target established in early December 2025.

### The Broader Target Range and Upside Potential

Despite the downward adjustment, analysts still see meaningful upside from current trading levels. Price projections span from a low of 40.40 kr to a high of 123.90 kr per share, indicating considerable disagreement among research teams on the company's trajectory. Against the latest closing price of 31.98 kr per share, the new average target implies potential appreciation of 129.64%—though this comes after the recent consensus pullback.

### Fund Positioning and Allocation Trends

A total of 18 investment funds and institutional entities maintain reported positions in Surgical Science Sweden AB, with no net change in the number of participating funds over the past quarter. However, subtle shifts in their commitment levels tell an interesting story. The collective portfolio weight dedicated to SUS averaged 0.09% across all participating funds, up by 4.03% from the prior period.

Institutional ownership expanded modestly, with total shares held by investment entities climbing 1.61% to reach 4.349 million shares during the three-month window.

### Notable Institutional Moves

**Largest Stakeholder**: The SMALLCAP WORLD FUND INC (SMCWX) maintains the most substantial position with 3.271 million shares, controlling 6.41% of the company. This holding remained flat quarter-over-quarter.

**Mixed Sentiment Among Mid-Size Players**: The Artisan International Small-Mid Fund (ARTJX) trimmed its stake from 297K to 252K shares (a 17.59% reduction), yet paradoxically increased its overall SUS allocation ratio by 5.70%. The iShares Core MSCI EAFE ETF (IEFA) took the opposite approach, growing its position from 211K to 213K shares—a 1.25% increase—while boosting its allocation weight by 1.35%.

The Fidelity Series International Small Cap Fund (FSTSX) held steady with 190K shares (0.37% ownership), while the iShares MSCI EAFE Small-Cap ETF (SCZ) maintained a smaller 118K-share position despite a modest uptick from 117K shares. Notably, SCZ reduced its SUS allocation ratio by 1.55% during the quarter.

These nuanced movements suggest institutional investors are recalibrating their exposure to Surgical Science Sweden AB even as some continue selective buying into the reduced valuation levels.